Overview

Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer

Status:
Completed
Trial end date:
2014-08-05
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the best dosage of Capecitabine and Tarceva combination in the setting of radiation and to assess treatment effectiveness, progression-free survival and overall survival.
Phase:
Phase 1
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Penn State University
Collaborator:
Genentech, Inc.
Treatments:
Capecitabine
Erlotinib Hydrochloride